HCW Biologics (HCWB) Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
HCWB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
HCW Biologics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.47 |
| 52 Week High | US$17.80 |
| 52 Week Low | US$0.25 |
| Beta | 0.90 |
| 1 Month Change | 30.89% |
| 3 Month Change | -57.55% |
| 1 Year Change | -93.91% |
| 3 Year Change | -99.15% |
| 5 Year Change | n/a |
| Change since IPO | -99.81% |
Recent News & Updates
Shareholder Returns
| HCWB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 15.1% | -4.3% | -0.2% |
| 1Y | -93.9% | 27.9% | 27.6% |
Return vs Industry: HCWB underperformed the US Biotechs industry which returned 27.9% over the past year.
Return vs Market: HCWB underperformed the US Market which returned 27.6% over the past year.
Price Volatility
| HCWB volatility | |
|---|---|
| HCWB Average Weekly Movement | 31.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: HCWB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HCWB's weekly volatility (32%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 36 | Hing Wong | www.hcwbiologics.com |
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company’s lead products include HCW9218, a clinical-stage bifunctional molecule, which has completed Phase 1 to treat chemotherapy-refractory solid tumor cancers and Phase 1b/2 to treat pancreatic cancer; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in phase 1 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201 and HCW9206, novel immunotherapeutic for memory-like natural killer cells, cancer, and pathogens; HCW11-006, an immune cell stimulator; HCW11-002 and HCW11-0027, which are immune checkpoint inhibitors to treat oncology and other senescence-associated indications; and HCW11-018, a fusions and immune cell engagers to treat cancer.
HCW Biologics Inc. Fundamentals Summary
| HCWB fundamental statistics | |
|---|---|
| Market cap | US$2.74m |
| Earnings (TTM) | -US$22.30m |
| Revenue (TTM) | US$54.23k |
Is HCWB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HCWB income statement (TTM) | |
|---|---|
| Revenue | US$54.23k |
| Cost of Revenue | US$43.39k |
| Gross Profit | US$10.85k |
| Other Expenses | US$22.31m |
| Earnings | -US$22.30m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.31 |
| Gross Margin | 20.00% |
| Net Profit Margin | -41,117.24% |
| Debt/Equity Ratio | 246.3% |
How did HCWB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 00:07 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HCW Biologics Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason McCarthy | Maxim Group |
| Michael Okunewitch | Maxim Group |